Implantable Cardioverter-Defibrillators and Prevention of Sudden Cardiac Death in Hypertrophic Cardiomyopathy

Authors:
  • PSPaolo Spirito
    Paolo Spirito
  • WSWin-Kuang Shen
    Win-Kuang Shen
  • THTammy S. Haas
    Tammy S. Haas
  • FFFrancesco Formisano
    Francesco Formisano
  • MLMark S. Link
    Mark S. Link
  • AEAndrew E. Epstein
    Andrew E. Epstein
  • AAAdrian K. Almquist
    Adrian K. Almquist
  • JDJames P. Daubert
    James P. Daubert
  • TLThorsten Lawrenz
    Thorsten Lawrenz
  • NEN. A. Mark Estes
    N. A. Mark Estes

Top Cited Papers
Open Access
Abstract
The risk of sudden death in patients with hypertrophic cardiomyopathy (HCM) has been known for almost 50 years.1-6 Indeed, this disease is the most common cause of sudden cardiac death in young people,1-6 including trained athletes.7 However, only in the last few years has the implantable cardioverter-defibrillator (ICD) been systematically used as a potentially life-saving treatment in high-risk patients with HCM.8-10 Since HCM represents a less common indication for ICDs than coronary artery disease11-14 it is important to document its effectiveness in a large HCM population. In addition, although there is little residual controversy regarding the appropriateness of ICDs for secondary prevention, considerable uncertainty persists concerning patient selection for prophylactic ICD therapy in HCM. Therefore, to provide insights into these important clinical issues, we report here the findings in a large, international, multicenter cohort of patients with HCM who have received an ICD.

This publication has 24 references indexed in Scilit: